What is the half-life of tirzepatide?
Tirzepatide has a plasma half-life of approximately 5 days (~120 hours) in humans. The long pharmacokinetic profile derives from engineering features — specifically a C20 fatty-acid sidechain attached via a γGlu-2xOEG spacer — that support reversible non-covalent binding to serum albumin in circulation. The 5-day half-life is the basis for the once-weekly subcutaneous dosing schedule used across the SURPASS and SURMOUNT clinical-trial programs.
What the research literature says
Tirzepatide’s pharmacokinetic profile was characterised in the Willard pharmacology work that established the compound as an imbalanced and biased dual receptor agonist (PMID 32730231). The fatty-acid sidechain on the peptide drives albumin-binding-mediated half-life extension — the same engineering strategy used in semaglutide and several other long-acting peptide therapeutics. Albumin binding sequesters the peptide in circulation, reduces renal clearance, and shields the molecule from proteolytic degradation, producing the multi-day plasma residence that supports a once-weekly dose interval.
The clinical-pharmacokinetic implications were established in the SURPASS program for type 2 diabetes (PMID 33236115, PMID 34170647 — head-to-head against semaglutide) and the SURMOUNT program for obesity without diabetes (PMID 37385275, PMID 38078870). The Willard mechanism work characterises the GIP receptor arm as biased — conformationally distinct from native GIP and producing a different downstream signalling profile — while the GLP-1 receptor arm engages in a fashion broadly similar to the established long-acting GLP-1 agonist class.
The dosing intervals tested across the clinical-trial programs (typically once weekly) align with the long plasma half-life. At steady state under once-weekly dosing, plasma concentrations of tirzepatide accumulate to a level that sustains both receptor arms continuously between doses, supporting the integrated metabolic effects observed across the programs.
Why this matters in research context
The long plasma half-life shapes both the experimental dosing cadence and the post-administration sampling design for tirzepatide research protocols. Acute single-dose pharmacology shows progressive accumulation to steady state over several once-weekly doses (typically 4-5 doses); washout from steady state similarly requires several weeks. Researchers designing tirzepatide protocols typically account for this slow approach to and departure from steady state when interpreting time-course data.
Related compounds
- Tirzepatide 10mg — the compound covered by this answer
- Semaglutide 10mg — parallel long-acting GLP-1 agonist (~7-day half-life) for cross-compound comparison
- Tirzepatide (glossary entry) — receptor pharmacology, clinical-trial overview
Related research questions
References
- Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020;5(17):e140532. [PMID 32730231]
- Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab 2021;106(2):388-396. [PMID 33236115]
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385(6):503-515. [PMID 34170647]
- Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet 2023;402(10402):613-626. [PMID 37385275]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Tirzepatide is sold strictly as a research-grade reagent for laboratory and bench research applications.